Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: FASEB J. 2020 Mar 5;34(4):5877–5891. doi: 10.1096/fj.201903045RR

Figure 3.

Figure 3.

Enz and Olaparib synergistically suppress HCC. A) HA22T and SK-HEP-1 cells were treated with serial dilutions of Enz (ENZ) and Olaparib (OLA) alone or with combination in the same concentration ratio of 4:3 for 5 days. The MTT assay was performed to determine cell viability. Data was analyzed using CompuSyn software based on median-effect principle and combination index theorem (CI<1, =1, and >1 indicates synergism, additive effect and antagonism, respectively). B) SK-HEP-1 cells were treated with 5 μM ENZ and 5 μM OLA alone or in combination. The MTT assay was performed to determine cell viability. Synergistic effects were determined by the Bliss independence model and by two-way ANOVA tests. C) SK-HEP-1 cells were treated with 10 μM ENZ and 10 μM OLA alone or in combination for 48 h. The protein levels of cleaved PARP (C-PARP) and GAPDH were detected using western blot.